Literature DB >> 30201376

Selective peroxisome proliferator-activated receptor-α modulator K-877 regulates the expression of ATP-binding cassette transporter A1 in pancreatic beta cells.

Tao Dong1, Jingya Lyu2, Hitomi Imachi2, Toshihiro Kobayashi2, Kensaku Fukunaga2, Seisuke Sato2, Tomohiro Ibata2, Takuo Yoshimoto2, Kazuko Yonezaki2, Hisakazu Iwama3, Guoxing Zhang4, Koji Murao2.   

Abstract

ATP-binding cassette transporter A1 (ABCA1) protein is a pivotal regulator of cholesterol and phospholipid efflux from cells to high-density lipoprotein (HDL) particles. Pancreatic ABCA1 functions in beta cell cholesterol homeostasis and affects insulin secretion. We investigated the effect of pemafibrate (K-877), a novel selective PPARα modulator (SPPARMα), on pancreatic ABCA1 expression. In vivo experiment, mice were divided into four treatment groups, namely, normal food plus placebo, high fat diet (HFD) plus placebo, normal food plus K-877 (0.3 mg/kg/day), or HFD plus K-877 (0.3 mg/kg/day), and treated for eight weeks. The results in vitro experiment indicate that K-877 treatment increased levels of ABCA1 mRNA, as well as protein, subsequently reduced the cellular cholesterol content in INS-1 cells. PPARα specific antagonist GW6471 attenuate K-877 induced ABCA1 expression in INS-1 cells. ABCA1 promoter activity increased with K-877 treatment at concentration 1 μM and 10 μM. Glucose-stimulated insulin secretion was ameliorated by K-877 treatment in INS-1 cells and isolated mouse islets. Although the expression of ABCA1 was reduced in mice with HFD treatment, both ABCA1 protein and mRNA levels were increased in mice with K-877 treatment. K-877 treatment improved glucose intolerance induced by HFD in mice. These findings raise the possibility that K-877 may affect insulin secretion by controlling ABCA1 expression in pancreatic beta cells.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  ABCA1; Cholesterol; K-877; PPARα

Mesh:

Substances:

Year:  2018        PMID: 30201376     DOI: 10.1016/j.ejphar.2018.09.015

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  4 in total

1.  Strategies to gain novel Alzheimer's disease diagnostics and therapeutics using modulators of ABCA transporters.

Authors:  Jens Pahnke; Pablo Bascuñana; Mirjam Brackhan; Katja Stefan; Vigneshwaran Namasivayam; Radosveta Koldamova; Jingyun Wu; Luisa Möhle; Sven Marcel Stefan
Journal:  Free Neuropathol       Date:  2021-12-13

2.  Effects of pemafibrate on glucose metabolism markers and liver function tests in patients with hypertriglyceridemia: a pooled analysis of six phase 2 and phase 3 randomized double-blind placebo-controlled clinical trials.

Authors:  Koutaro Yokote; Shizuya Yamashita; Hidenori Arai; Eiichi Araki; Mitsunori Matsushita; Toshiaki Nojima; Hideki Suganami; Shun Ishibashi
Journal:  Cardiovasc Diabetol       Date:  2021-05-04       Impact factor: 9.951

Review 3.  Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases.

Authors:  Shizuya Yamashita; Daisaku Masuda; Yuji Matsuzawa
Journal:  Curr Atheroscler Rep       Date:  2020-01-23       Impact factor: 5.113

4.  Combination therapy with pemafibrate (K-877) and pitavastatin improves vascular endothelial dysfunction in dahl/salt-sensitive rats fed a high-salt and high-fat diet.

Authors:  Masatoki Yoshida; Kazufumi Nakamura; Toru Miyoshi; Masashi Yoshida; Megumi Kondo; Kaoru Akazawa; Tomonari Kimura; Hiroaki Ohtsuka; Yuko Ohno; Daiji Miura; Hiroshi Ito
Journal:  Cardiovasc Diabetol       Date:  2020-09-26       Impact factor: 9.951

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.